S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:SNY

Sanofi (SNY) Stock Price, News & Analysis

$49.54
-0.21 (-0.42%)
(As of 03/27/2024 ET)
Today's Range
$49.53
$49.85
50-Day Range
$45.75
$51.88
52-Week Range
$42.63
$57.82
Volume
2.53 million shs
Average Volume
1.58 million shs
Market Capitalization
$125.32 billion
P/E Ratio
20.99
Dividend Yield
2.79%
Price Target
$55.00

Sanofi MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
11.0% Upside
$55.00 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.98mentions of Sanofi in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.27%
From $4.19 to $4.83 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.20 out of 5 stars

Medical Sector

352nd out of 939 stocks

Pharmaceutical Preparations Industry

160th out of 422 stocks

SNY stock logo

About Sanofi Stock (NASDAQ:SNY)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

SNY Stock Price History

SNY Stock News Headlines

Wall Street Lunch: Calhoun To Leave Boeing
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
12 Most Profitable Biotech Stocks To Invest In
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
SNY Sep 2024 50.000 call
3 Cash Cow Dividend Stocks for Outsized Income & Upside
See More Headlines
Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/01/2024
Today
3/28/2024
Next Earnings (Confirmed)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SNY
Employees
86,088
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$55.00
High Stock Price Target
$55.00
Low Stock Price Target
$55.00
Potential Upside/Downside
+11.0%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$5.84 billion
Pretax Margin
15.40%

Debt

Sales & Book Value

Annual Sales
$46.61 billion
Cash Flow
$6.41 per share
Book Value
$31.81 per share

Miscellaneous

Outstanding Shares
2,529,610,000
Free Float
2,504,311,000
Market Cap
$125.32 billion
Optionable
Optionable
Beta
0.61

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Paul HudsonMr. Paul Hudson (Age 57)
    CEO & Director
    Comp: $4.08M
  • Mr. Jean-Baptiste Chasseloup de ChatillonMr. Jean-Baptiste Chasseloup de Chatillon (Age 59)
    Executive VP & CFO
  • Ms. Madeleine Roach (Age 40)
    Executive VP & Head of Business Operations
  • Mr. Laurent Gilhodes
    Principal Accounting Officer and Vice President of Corporate Accounting
  • Dr. Josephine Fubara
    Chief Science Officer of Consumer Health Care
  • Eva Schaefer-Jansen
    Head of Investor Relations
  • Mr. Dante Beccaria
    Global Compliance Officer & VP
  • Mr. Roy Papatheodorou (Age 46)
    Executive VP & General Counsel
  • Mr. Josep Catlla
    Head of Communications
  • Mr. Pierre Chancel (Age 67)
    Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing

Should I Buy Sanofi Stock? SNY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Sanofi was last updated on Sunday, March 24, 2024 at 3:26 PM.

Pros

Here are some ways that investors could benefit from investing in Sanofi:

  • Sanofi has a diverse portfolio of specialty care products, including DUPIXENT, neurology and immunology treatments, rare diseases medications, and oncology therapies, providing a wide range of revenue streams.
  • The company has collaborations with various biotech firms like Exscientia, ABL Bio, and Seagen Inc., enhancing its pipeline with innovative treatments for oncology and immunology, which could lead to potential breakthroughs and market advantages.
  • Sanofi's stock price has shown stability and growth potential, with a market cap of $121.42 billion, a PE ratio of 20.40, and a price-to-earnings-growth ratio of 1.77, indicating a solid financial standing.
  • Continued investment in research and development, exemplified by partnerships with companies like Skyhawk Therapeutics and Adagene Inc., demonstrates a commitment to innovation and future growth.
  • The company's global presence and established brand reputation in healthcare, with a history dating back to 1973, provide a level of stability and trust for investors.

Cons

Investors should be bearish about investing in Sanofi for these reasons:

  • Sanofi faces competition in the pharmaceutical industry, which could impact market share and pricing strategies, leading to potential revenue challenges.
  • The company's stock performance has experienced fluctuations, with a one-year low of $42.63 and a high of $57.82, indicating volatility that may pose risks to investors.
  • Regulatory changes and challenges in different regions where Sanofi operates, such as the United States and Europe, could affect product approvals, pricing, and market access, impacting financial performance.
  • Dependency on key products like DUPIXENT and established prescription medications for a significant portion of revenue may expose Sanofi to risks related to patent expirations, generic competition, and market shifts.
  • External factors like global economic conditions, healthcare policies, and public health crises can influence the demand for Sanofi's products and services, introducing uncertainties for investors.

SNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Sanofi stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNY, but not buy additional shares or sell existing shares.
View SNY analyst ratings
or view top-rated stocks.

What is Sanofi's stock price target for 2024?

6 equities research analysts have issued 1-year price objectives for Sanofi's stock. Their SNY share price targets range from $55.00 to $55.00. On average, they predict the company's stock price to reach $55.00 in the next year. This suggests a possible upside of 11.0% from the stock's current price.
View analysts price targets for SNY
or view top-rated stocks among Wall Street analysts.

How have SNY shares performed in 2024?

Sanofi's stock was trading at $49.73 at the start of the year. Since then, SNY stock has decreased by 0.4% and is now trading at $49.54.
View the best growth stocks for 2024 here
.

When is Sanofi's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our SNY earnings forecast
.

How can I listen to Sanofi's earnings call?

Sanofi will be holding an earnings conference call on Thursday, April 25th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Sanofi's earnings last quarter?

Sanofi (NASDAQ:SNY) released its quarterly earnings results on Thursday, February, 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by $0.05. The firm earned $11.76 billion during the quarter, compared to analysts' expectations of $13.02 billion. Sanofi had a trailing twelve-month return on equity of 27.47% and a net margin of 12.56%.

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Tuesday, May 30th. Investors of record on Wednesday, May 31st will be paid a dividend of $1.377 per share on Friday, June 23rd. This represents a yield of 2.94%. The ex-dividend date is Tuesday, May 30th.
Read our dividend analysis for SNY
.

Is Sanofi a good dividend stock?

Sanofi (NASDAQ:SNY) pays an annual dividend of $1.38 per share and currently has a dividend yield of 2.78%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 58.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SNY will have a dividend payout ratio of 28.57% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for SNY.

What is Paul Hudson's approval rating as Sanofi's CEO?

277 employees have rated Sanofi Chief Executive Officer Paul Hudson on Glassdoor.com. Paul Hudson has an approval rating of 94% among the company's employees. This puts Paul Hudson in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Amgen (AMGN), Broadcom (AVGO), Boeing (BA), Alibaba Group (BABA), Bank of America (BAC) and BP (BP).

Who are Sanofi's major shareholders?

Sanofi's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Dodge & Cox (3.09%), Fisher Asset Management LLC (0.57%), Fisher Asset Management LLC (0.56%), Boston Partners (0.52%), Nuveen Asset Management LLC (0.18%) and Envestnet Asset Management Inc. (0.10%).
View institutional ownership trends
.

How do I buy shares of Sanofi?

Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Sanofi have any subsidiaries?
The following companies are subsidiares of Sanofi: A. Nattermann & Cie. GmbH, AO Sanofi Russia, Ablynx, Ablynx N.V., Allston Landing Limited Partnership, Aventis Inc., Aventis Pharma (Manufacturing) Pte. Ltd, Aventis Pharma Limited, Aventis Pharma S.A., Aventis S.A., Aventisub LLC, Bioverativ, Bioverativ Inc., Bioverativ Therapeutics Inc., Bioverativ U.S.LLC, Carraig Insurance DAC, Chattem Inc., Chinoin Private Co. Ltd, Francopia, Genfar S.A., Genzyme Corporation, Genzyme Europe B.V., Genzyme Flanders BVBA, Genzyme Global Sarl, Genzyme Ireland Limited, Genzyme Limited, Genzyme Polyclonals SAS, Genzyme Therapeutic Products Limited Partnership, Genzyme Therapeutics Limited, Genzyme de Argentina S.A., Hoechst GmbH, Kiadis Pharma, Limited Liability Company Sanofi-Aventis Ukraine, PT Aventis Pharma, Principia BioPharma, SSP Co. Ltd, Sanofi (Beijing) Pharmaceuticals Co.Ltd, Sanofi (China) Investment Co. Ltd, Sanofi (Hangzhou) Pharmaceuticals Co. Ltd, Sanofi A/S, Sanofi AB, Sanofi Arabia Trading Company Limited, Sanofi Aventis NA Holding Inc., Sanofi Belgium, Sanofi Biotechnology, Sanofi Chimie, Sanofi Egypt, Sanofi Finance Ireland limited, Sanofi Foreign Participations B.V., Sanofi Healthcare India Private Limited, Sanofi Ilac Sanayi ve Ticaret A.S., Sanofi India Limited, Sanofi K.K., Sanofi Mature IP, Sanofi Medley Farmaceutica Ltda, Sanofi Nichi-Iko K.K., Sanofi Oy, Sanofi Pasteur, Sanofi Pasteur Asi Ticaret A.S., Sanofi Pasteur Biologies Co. Ltd, Sanofi Pasteur Europe, Sanofi Pasteur Inc., Sanofi Pasteur India Private Ltd, Sanofi Pasteur Limited, Sanofi Pasteur Ltd, Sanofi Pasteur NVL, Sanofi Pasteur S.A. de C.V., Sanofi Produtos Farmaceuticos Lda, Sanofi Romania SRL, Sanofi S.p.A., Sanofi Saglik Urunleri Limited Sirketi, Sanofi Taiwan Co. Ltd, Sanofi US Corporation, Sanofi US Services Inc., Sanofi Vaccine Technologies, Sanofi Winthrop Industrie, Sanofi-Aventis (Malaysia) SDN. BHD., Sanofi-Aventis (Suisse) SA, Sanofi-Aventis (Thailand) Ltd, Sanofi-Aventis A.E.B.E., Sanofi-Aventis Algérie, Sanofi-Aventis Argentina S.A., Sanofi-Aventis Australia Pty Ltd, Sanofi-Aventis Canada Inc., Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis France, Sanofi-Aventis GmbH, Sanofi-Aventis Groupe, Sanofi-Aventis Gulf FZE, Sanofi-Aventis Healthcare Pty Ltd, Sanofi-Aventis Hong-Kong Limited, Sanofi-Aventis Ireland Ltd, Sanofi-Aventis Israël Ltd, Sanofi-Aventis Korea Co. Ltd, Sanofi-Aventis Liban s.a.l., Sanofi-Aventis Maroc, Sanofi-Aventis Netherlands B.V., Sanofi-Aventis Norge AS, Sanofi-Aventis Pakistan Limited, Sanofi-Aventis Participations, Sanofi-Aventis Philippines Inc., Sanofi-Aventis Private Co Ltd, Sanofi-Aventis Recherche & Développement, Sanofi-Aventis S.A., Sanofi-Aventis Singapore Pte. Ltd, Sanofi-Aventis South Africa (Pty) Ltd, Sanofi-Aventis Sp. z.o.o., Sanofi-Aventis U.S. LLC, Sanofi-Aventis UK Holdings Limited, Sanofi-Aventis Winthrop S.A. de C.V., Sanofi-Aventis de Colombia S.A., Sanofi-Aventis de Mexico S.A. de C.V., Sanofi-Aventis de Panama S.A., Sanofi-Aventis de Venezuela S.A., Sanofi-Aventis del Ecuador S.A., Sanofi-Aventis del Peru S.A., Sanofi-Aventis s.r.o., Sanofi-Synthelabo (India) Private Ltd, Sanofi-aventis Vietnam Company Limited, Shenzhen Sanofi pasteur Biological Products Co Ltd, Synthorx, VaxServe Inc., sanofi-aventis Puerto Rico Inc, and sanofi-aventis Slovakia s.r.o..
Read More
This page (NASDAQ:SNY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners